Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines.

Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines. Abstract Text:

    yanmin wanYanmin Wan,lan wuLan Wu,lianxing liuLianxing Liu,jianqing xuJianqing Xu,ying liuYing Liu,yong liuYong Liu,yiming shaoYiming Shao,

    HIV-1 pandemic posed an unprecedented challenge to the global health and it is believed that an effective vaccine will be the final solution against HIV-1. HIV-1 envelope is the primary immunogen in developing neutralization antibody based HIV vaccine. To define the suitable Env derived immunogen, we systemically compared the immunogenicity of gp140 and gp145 in a DNA vaccination alone and a prime-boost modalities. Two DNA vaccines and two recombinant Tiantan vaccinia vaccines (rTTV) were constructed for vaccination of female Balb/c mice. Elispot assay was used to read out the T cell immunity and ELISA assay was used to quantify antibody immunity. PLL (poly-L-leucine)-ELISA assay was used in linear antibody epitope mapping. Mice primed with gp145 tended to elicit more Env-specific T cells responses than those primed with gp140, significant difference was observed in DNA immunization alone. The ultimate T cell responses in prime-boost regimen tend to be determined mainly by the priming efficacy. Linear antibody epitope mapping displayed that sera raised by gp145 priming were vigorously reactive to more peptides than that by gp140. Our data demonstrated HIV-1 Thailand B-derived gp145 may raise higher T-cell responses and broader linear peptide-specific antibody responses than gp140 does. However, it remains to be determined that how these observations are relevant to the neutralization of antibody activities.

    Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines. Publishing Authors By Initials

    y wanY Wan,l wuL Wu,l liuL Liu,j xuJ Xu,y liuY Liu,y liuY Liu,y shaoY Shao,

    For similar viruses: dna viruses: poxviridae: chordopoxvirinae: orthopoxvirus: vaccinia virus research abstracts see: viruses: dna viruses: poxviridae: chordopoxvirinae: orthopoxvirus: vaccinia virus research

    PUBMED ID PMID:

    MEDLINE DATE:

    Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines. Journal Published:

    PUBLICATION TYPE: Research Support, Non-U.S. Gov

    Journal: Vaccine

    VOLUME: 25

    Page Numbers: 4949-59

    Journal Abbreviation: Vaccine

    ISSN: 0264-410X

    DAY: 26

    MONTH: 02

    YEAR: 2007

    Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 8406899

    Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines. Keywords Mesh Terms:

    KEYWORDS: Vaccinia virus

    MESH TERMS: immunology

    Chemical & Substance for Abstract: Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines. Information

    Substance Name: Vaccines, Synthetic

    Registry Number: 0

    Grant and Affiliation Information for Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines.

    AFFILIATION: State Key Laboratory for Infectious Diseases Prevention and Control, National Center for AIDS/STD Control and Prevention (NCAIDS), China CDC, 27 Nanwei Road, Xuanwu District, Beijing 100050, China.

    Country: Netherlands

    Netherlands Research PublicationNetherlands Research Publication

    AGENCY: United States NIAID

    GRANT: U19 AI 51915

    ACRONYM: AI

    MEDLINETA: Vaccine

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News